Table 2.
Studies assessing HRQL in Hodgkin lymphoma patients (N = 65)
| Primary Author | Year | Design | Study Type | Timepoints (as reported) | N (HL Specific) | Age (HL specific) | Tx Status | Measures | Domains Assessed | Quality Score |
|---|---|---|---|---|---|---|---|---|---|---|
| Fobair P [26] | 1986 | Cohort | Cross-sectional | Median 9 years post treatment | 403 | 36.3 mean | Off | CES-D, Study-specific questionnaire | Domain, Symptom | 6 |
| Kornblith AB [22] | 1990 | Cohort | Cross-sectional | 6.3 years mean post treatment | 273 | 37 mean | Off | PAIS-SR, BSI, POMS, IES, Global Sexual Satisfaction Index | Domain | 5 |
| Chao NJ [37] | 1992 | Cohort | Longitudinal | <1 year post treatment | 24 | N/S | Off | Study-specific questionnaire | MultiD | 2 |
| Kornblith AB [23] | 1992 | Cohort | Cross-sectional | Mean 6.3 years post treatment | 273 | 37 mean | Off | PAIS-SR, BSI, POMS, Global Sexual Satisfaction Index | Domain | 6 |
| Kornblith [48] AB | 1992 | Cohort | Cross-sectional | Mean 2.2 years post treatment | 93 | 35 median | Off | PAIS-SR, BSI, POMS, IES | Domain | 4 |
| Bloom JR [49] | 1993 | Comparator: Cohort | Cross-sectional | 1 or more years post treatment | 85 | 32.3 mean | Off | POMS, CES-D, Social Activity Scale | Domain | 6 |
| van Tulder MW [30] | 1994 | Comparator: Cohort | Cross-sectional | Mean 14 years since diagnosis | 81 | 43.6 mean | Off | SF-36, Maudsley Martital Questionnaire | MultiD, Other | 6 |
| Joly F [38] | 1996 | Comparator: Case Control | Cross-sectional | Mean 10 years since diagnosis | 93 | 42 mean | Off | EORTC QLQ-C30, Study-specific questionnaire | MultiD, Other | 6 |
| Norum J [50] | 1996 | Cohort | Cross-sectional | Median 48 months since diagnosis | 42 | 38 median | Off | IES, VAS | Domain, Other | 4 |
| Norum J [51] | 1996 | Cohort | Cross-sectional | Median 48 months since diagnosis | 42 | 38 median | Off | EuroQol | MultiD | 4 |
| Norum J [52] | 1996 | Cohort | Cross-sectional | Median 48 months since diagnosis | 42 | 38 median | Off | EORTC QLQ-C30 | MultiD | 3 |
| Abrahamsen AF [29] | 1998 | Cohort | Cross-sectional | Mean 12 years since diagnosis | 459 | 44 median | Off | Study-specific questionnaire | Domain | 6 |
| Kornblith AB [24] | 1998 | Comparator: Cohort | Cross-sectional | Mean 5.9 years post treatment | 273 | 37 median | Off | PAIS-SR, BSI, POMS, IES | Domain | 6 |
| Greil R [13] | 1999 | Cohort | Cross-sectional | Mean 10.5 years since diagnosis | 126 | 36.9 mean | Off | EORTC QLQ-C30 | MultiD | 6 |
| Kaasa S [53] | 1999 | Comparator: Cohort | Cross-sectional | 3–20 years post treatment | 459 | 44 mean | Off | SF-36, FQ | MultiD, Symptoms | 5 |
| Loge JH [54] | 1999 | Cohort | Cross-sectional | Mean 12.2 years since diagnosis | 459 | 44 mean | Off | HADS, FQ | Domain, Symptom | 6 |
| Loge JH [55] | 1999 | Cohort | Cross-sectional | Mean 12.2 years since diagnosis | 459 | 44 mean | Off | SF-36 | MultiD | 6 |
| Van Schaik CS [56] | 1999 | Cohort | Cross-sectional | Median 21.9 years since diagnosis | 33 | 21.9 median | Off | HUI2, HUI3 | MultiD | 3 |
| Loge JH [32] | 2000 | Cohort | Cross-sectional | 3–23 years post treatment | 421 | 19–74 years | Off | FQ, HADS, Study-specific questionnaire | Domain. Symptom | 6 |
| Barr RD [57] | 2001 | Comparator: Cohort | Cross-sectional | Completed treatment at least 2 years prior | 19 | N/S | Off | HUI | MultiD | 2 |
| Cameron CL [58] | 2001 | Cohort | Cross-sectional | Median 7 years since diagnosis | 272 | 37 mean | Off | PAIS-SR, Symptom Report | Domain, Symptom | 4 |
| Knobel H [35] | 2001 | Cohort | Cross-sectional | Mean 9 years since diagnosis | 92 | 37 mean | Off | FQ | Symptom | 6 |
| Zabora J [59] | 2001 | Cohort | Cross-sectional | 58 % diagnosed within 90 days from study | 135 | N/S | Both | BSI | Domain | 3 |
| Zebrack BJ [43] | 2002 | Comparator: Cohort | Cross-sectional | Mean 16.2 years since diagnosis | 1843 | 30.8 mean | Off | BSI | Domain | 5 |
| Ganz PA [10] | 2003 | Comparator: RCT | Longitudinal | Trial registration (since diagnosis) | 244 | 31.4 STLI, 33.7 CMT median | Both | SF-36, CARES-SF, SDS | MultiD, Symptom | 4 |
| Gil-Fernández JJ [27] | 2003 | Cohort | Cross-sectional | Median 7.6 years since diagnosis | 46 | 43 mean | Off | EORTC QLQ-C30, HADS | MultiD, Other | 5 |
| Oldervoll LM [36] | 2003 | Cohort | Longitudinal | Mean post treatment: 6.6 years fatigued patients; 4.9 years non-fatigued patients | 53 | 41 fatigue, 40 non-fatigued mean | Off | SF-36, FQ | MultiD, Symptom | 5 |
| Rüffer JU [33] | 2003 | Comparator: Case Control | Cross-sectional | Median 5.2 years since diagnosis | 818 | 31 median | Off | EORTC QLQ-C30, MFI, Life Situation Questionnaire | MultiD, Symptom | 5 |
| Wettergren L [60] | 2003 | Cohort | Cross-sectional | Mean 14 years since diagnosis | 121 | 47 mean | Off | SEIQol-DW | MultiD | 5 |
| Adams MJ [16] | 2004 | Cohort | Cross-sectional | Median 14.3 years since diagnosis | 48 | 31.9 median | Off | SF-36, Study-specific questionnaire | MultiD | 4 |
| Wettergren L [28] | 2004 | Cohort | Cross-sectional | Mean 13 years since diagnosis | 121 | 47 median | Off | SF-12, SEIQoL-DW, HADS | MultiD, Domain | 6 |
| Hjermstad MJ [61] | 2005 | Cohort | Cross-sectional | Median 16.3 years since diagnosis | 496 | 46 median | Off | FQ | Symptom | 6 |
| Ng AK [34] | 2005 | Comparator: Cohort | Cross-sectional | Median 15 years since diagnosis | 511 | 44 median | Off | FACIT-Fatigue | Symptom | 6 |
| Wettergren L [62] | 2005 | Cohort | Cross-sectional | Median 14 years since diagnosis | 121 | NS | Off | SF-12, SEIQoL-DW | MultiD | 2 |
| Hjermstad MJ [63] | 2006 | Cohort | Cross-sectional | Median 16.3 years since diagnosis | 479 | 46 mean | Off | SF-36, FQ | MultiD, Symptom | 5 |
| Mols F [21] | 2006 | Cohort | Cross-sectional | 5–15 years since diagnosis | 132 | NS | Off | SF-36, QoL-CS | MultiD | 6 |
| Absolom K [64] | 2007 | Cohort | Cross-sectional | 15.7 years mean since diagnosis | 50 | 39.7 mean | Off | SF-12, HADS | MultiD, Domain | 5 |
| Aksnes LH [65] | 2007 | Comparator: Cohort | Cross-sectional | Mean since diagnosis: 14 years for males, 11 years for females | 89 | 35 mean | Off | SF-36, HADS, FQ | MultiD, Domain, Symptom | 4 |
| Oldervoll LM [66] | 2007 | Cohort | Cross-sectional | Mean 17 years since diagnosis | 476 | 46 mean | Off | FQ | Symptom | 5 |
| Goodman KA [19] | 2008 | Cohort | Cross-sectional | Median 12 years post treatment | 60 | 43 median | Off | EORTC QLQ-C30 | MultiD | 6 |
| Mulrooney DA [67] | 2008 | Comparator: Cohort | Cross-sectional | At least 15 years since diagnosis | 995 | NS | Off | FACIT-Fatigue, Pittsburgh Slee Quality Index, Epworth Sleepiness Scale | Symptoms | 4 |
| Shimoda S [68] | 2008 | Cohort | Cross-sectional | Mean 16.5 years since diagnosis | 15 | NS | Off | HUI3 | MultiD | 2 |
| Kiserud CE [14] | 2009 | Cohort | Cross-sectional | Mean 15.2 follow up years | 138 | 45.7 mean | Off | BSFI, Fatigue questionnaire, HADS, SF-36 | MultiD, Symptom, Domain | 6 |
| Heutte N [11] | 2009 | Comparator: RCT | Longitudinal | Mean 7.5 years since diagnosis | 935 | 31 median | Off | EORTC QLQ-C30, MFI, Sexual Function Scale | MultiD, Symptoms | 6 |
| Brandt J [69] | 2010 | Cohort | Cross-sectional | Median since diagnosis: HDCT 11 years, conventional chemotherapy 3.5 years | 98 | 46 HDCT, 41 conventional median | Off | EORTC QLQ-C30, EQ-5D | MultiD | 6 |
| Klaassen RJ [40] | 2010 | Cohort | Longitudinal | 2 weeks after first course of chemotherapy | 49 | 14.7 mean | Both | PedsQL, HUI2, HUI3, EuroQol, Lanksy Play-Performance Score | MultiD, Other | 4 |
| Klaassen RJ [41] | 2010 | Comparator: Cohort | Longitudinal | 2 weeks after first course of chemotherapy | 49 | 14.7 mean | Both | PedsQL, HUI2, HUI3, EuroQol, Lanksy Play-Performance Score | MultiD, Other | 2 |
| Miltényi Z [17] | 2010 | Cohort | Cross-sectional | Mean 9.8 years since diagnosis | 168 | 43.11 median | Off | EORTC QLQ-C30 | MultiD | 6 |
| Baptista RLR [70] | 2012 | Cohort | Cross-sectional | Median 7 years since diagnosis | 200 | 29 median | Off | MFI | Symptom | 4 |
| Khimani N [18] | 2013 | Cohort | Longitudinal | Median 24 years since diagnosis | 273 | 52 median | Off | SF-36, FACIT-Fatigue | MultiD, Symptom | 5 |
| Minn AY [20] | 2012 | Cohort | Cross-sectional | Median 10.2 years post treatment | 71 | 26 median | Off | EORTC QLQ-C30 | MultiD | 5 |
| Behringer K [12] | 2013 | Comparator: RCT | Longitudinal | At diagnosis | 3208 | 36.4 mean | Both | EORTC QLQ-C30, MFI, Sexual Health Scale | MultiD, Symptoms | 6 |
| Greaves P [39] | 2014 | Comparator: Cohort | Cross-sectional | Mean 20.3 years since diagnosis | 280 | 53.1 mean | Off | FACT-BMT, IOC, Study-specific questionnaire | MultiD, Other | 5 |
| Hamre H [44] | 2013 | Comparator: Cohort | Cross-sectional | Median 21.5 years since diagnosis | 68 | 35 median | Off | FQ | Symptom | 5 |
| Kim S [71] | 2014 | Cohort | Cross-sectional | Mean 6.7 years since diagnosis | 58 | 43.3 mean | Off | EORTC QLQ-C30, HADS | MultiD, Domain | 6 |
| Roper K [72] | 2013 | Cohort | Longitudinal | At completion of planned therapy | 40 | 30.9 mean | Off | SF-12, HADS, SDS, IOC | MultiD, Domain, Other | 4 |
| Soares A [45] | 2013 | Cohort | Cross-sectional | Median 7 years since diagnosis | 200 | 29 median | Off | SF-12, QOL-CS, MOS-SSS, MFI | MultiD, Symptom | 4 |
| Vissers PAJ [15] | 2013 | Cohort | Cross-sectional | Mean 5 years since diagnosis | 150 | 47 mean | Off | EORTC QLQ-C30 | MultiD | 6 |
| Calaminus G [46] | 2014 | Cohort | Cross-sectional | Mean 15.3 years since diagnosis | 725 | 28.44 mean | Off | EORTC QLQ-C30 | MultiD | 6 |
| Daniels LA [31] | 2014 | Cohort | Cross-sectional | Mean 4.6 years since diagnosis | 180 | 46 mean | Off | EORTC QLQ-C30, Fatigue Assessment Scale, Study-specific questionnaire | MultiD, Symtom, Domain | 6 |
| Daniels LA [73] | 2014 | Cohort | Longitudinal | Mean 21 years since diagnosis | 43 | 47 mean | Off | EORTC QLQ-C30, Fatigue Assessment Scale, HADS | MultiD, Domain, Symptom | 4 |
| Oerlemans S [25] | 2014 | Comparator: Case Control | Longitudinal | Mean 4.7 years since diagnosis | 180 | 46.1 mean | Off | EORTC QLQ-C30, HADS | MultiD, Domain | 6 |
| Vermaete N [47] | 2014 | Comparator: Cohort | Longitudinal | Before the start of chemotherapy | 12 | 47 mean | Both | EORTC QLQ-C30, Distress Barometer | MultiD, Domain | 5 |
| Kiserud CE [74] | 2015 | Cohort | Cross-sectional | Median 16 years since diagnosis | 131 | 46 median | Off | Fatigue questionnaire, HADS, SF36, | Symptom, MultiD | 5 |
| Husson O [42] | 2015 | Comparator: Cohort | Cross-sectional | Mean 5.3 years since diagnosis | 150 | 46.6 mean | Off | Fatigue assessment scale | Symptom | 4 |
Abbreviations: Tx treatment, MultiD multidimensional, HL Hodgkin’s Lymphoma, RCT randomized controlled trial, EORTC QLQ-C30 European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire, SF-36/SF-12 Short Form, HUI Health Utilities Index, QOL-CS Quality of Life-Cancer Survivors, CES-D Center for Epidemiologic Studies Depression Scale, GSSI Global Sexual Satisfaction Index, IES Impact of Event Scale, VAS Visual Analogue Scale, CARES-SF Cancer Rehabilitation Evaluation System-Short Form, SDS Symptom Distress Scale, SEIQol-DW Schedule for the Evaluation of the Individual Quality of Life-Direct Weighting, PedsQL Pediatric Quality of Life Inventory, MOS-SSS Medical Outcomes Study-Social Support Survey, FACT-BMT Functional Assessment of Cancer Therapy—Bone Marrow Transplant, FQ Fatigue Questionnaire, MFI Multi-Dimensional Fatigue Inventory, FACIT-Fatigue Functional Assessment of Chronic Illness Therapy-Fatigue, HADS Hospital Anxiety and Depression Scale, BSI Brief Symptom Inventory, POMS Profile of Mood States, PAIS Psychosocial Adjustment to Illness Scale, HDCT high dose chemotherapy, STLI subtotal lymphoid irradiation, CMT combined modality treatment, NS not stated